DDInter1607 DDInter1352
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931]
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Osimertinib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Osimertinib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Ivacaftor
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Melatonin
Melatonin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may lead to a major life threatening interaction when taken with {v} Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Caffeine
Caffeine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Ritonavir {u} (Compound) causes {v} (Side Effect) Urinary retention
Urinary retention {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Osimertinib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Ritonavir {u} (Compound) causes {v} (Side Effect) Bone disorder
Bone disorder {u} (Side Effect) is caused by {v} (Compound) Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Osimertinib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Osimertinib
Ritonavir (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Ritonavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Melatonin (Compound) and Melatonin may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a minor interaction that can limit clinical effects when taken with Caffeine and Caffeine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Ritonavir (Compound) causes Urinary retention (Side Effect) and Urinary retention (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Ritonavir (Compound) causes Bone disorder (Side Effect) and Bone disorder (Side Effect) is caused by Formoterol (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib